Gordie Nye

• LUUM is an Oakland, CA based startup which has created a pioneering combination of ROBOTICS (the precise and repetitive movements required to apply lash extensions make it a perfect application for advanced robotics), COMPUTER VISION (the system “sees” a client’s eyelashes on a micro scale and reacts in real time to movements or environmental changes), and ARTIFICIAL INTELLIGENCE (neural networks learn from each client and improve the performance of the system). We recently closed our Series A and are in the process of finalizing the development of our commercial robot. Our partnerships with Ulta Beauty (NASDAQ:ULTA) and Nordstrom have been tremendous successes.
• Oversaw financial performance, driving budgetary discipline and resource allocation strategies.
• Mentored executive team, promoting leadership development and organizational expansion as we evolve from development-stage to commercial-stage.

• Based in Cambridge UK, Inotec AMD created the NATROX O2 device which was commercially launched in 2016. The NATROX O2 is designed to deliver continuous topical oxygen to the bed of a chronic, hard-to-heal wound. It is an easy-to-use, patented, compact, battery-operated device which stimulates wound healing and reduces associated wound pain. After several setbacks (both externally induced and internally induced), NATROX is poised for global growth should it be properly funded.
• One month after accepting the Chairman role, the NATROX CEO resigned, and I was asked to become Interim CEO. Soon thereafter I learned that the lead investor wanted to initiate a "fire sale" of the business because they were out of investment capital.
• This strategic shift conflicted with my vision for NATROX: with two more years of product development and regulatory work/investment, I believe that the business could revolutionize the chronic wound category for patients, providers, and payors.

• ClearIT, Inc. has developed a novel approach to tattoo removal – The ERASER System – for the healthful, pain-free, affordable, and time-efficient tattoo removal. Proof of concept in animals was completed in 2020; human feasibility was underway; we were partnered with Battelle (https://www.battelle.org) in our “productization” phase; we expected to be commercially available in mid- 2026. However, a new investor changed our regulatory, clinical, and commercial direction as of July 2023; our team resigned at that time.

• Atlantic Therapeutics was a venture-backed corporate carve-out that invented an exciting women’s health device that non-invasively treats stress urinary incontinence. Following our receipt of a de novo 510(k) in November 2018, I added the role of interim CEO of Americas and recruited our Americas commercial team. In 2019, we launched an integrated digital media and public relations campaign to drive patients to our website (www.myinnovo.com). In February 2020, we received OTC classification from FDA, removing the requirement that a patient get a prescription for Innovo. We launched our DTC television campaign in mid-March 2020. I stepped off the Board upon the replacement of our founding CEO. In September 2023, the Company was acquired by Caldera Medical.

• Recruited in December 2014 as Employee #1 to build a product platform and commercial company around in-licensed intellectual property from Massachusetts General Hospital. The company began with substantial (>$21M) founding capital, provided by a publicly traded holding company (NYSE:VATE). In June 2019, we closed on a $30M Series B which has been provided by China Grand/Huadong Medicine. R2 is currently commercializing a revolutionary treatment system called Glacial Rx (https://glacialskin.com) to effect skin tone evening and lightening non-invasively. Since R2 had to execute an APAC-focused launch (our Series B investor has secured exclusive distribution rights in 32 APAC countries), I stepped out of the day-to-day business and recruited senior leadership that is steeped in expertise in that region.

• I left the REVA Board in July 2017 to become Chairman at Atlantic Therapeutics. REVA has developed a novel cardiology product (a bioresorbable stent) and completed its initial public offering in December 2010 trading on the Australian Securities Exchange as “RVA”. I was an early angel investor in 1998 and became the interim CEO from 1999 until 2003. I was the Chairman of the Compensation Committee.

• Systagenix, formerly Johnson & Johnson’s wound care business, was carved out of JNJ by One Equity Partners in 2008. In late 2013, Systagenix was sold to KCI.

• Founded in 2005, ZELTIQ developed a technology called “CoolSculpting” that reduces unwanted bulges in the tummy and midsection noninvasively in an office setting, using cold therapy (www.coolsculpting.com). When I joined the firm in September of 2009, the Company had less than one quarter of cash remaining and had been attempting to raise a Series D financing for 14 months. I was recruited to develop a strategy for the “commercialization phase”. We finished 2009 with under $2 million in Net Revenues.
• Over my term at the Company (2 years and 9 months), we achieved the following:

A) We branded our procedure CoolSculpting, now an internationally recognized consumer brand.

B) We implemented a category-changing “recurring revenue” model that ultimately made ZELTIQ the most valuable capital equipment company in the history of medical aesthetics.

C) We raised our Series D (in May 2010), bringing in $25 million – more than sufficient to carry ZELTIQ past break-even.

D) We established distribution – both direct (six markets, including the USA) and indirect – in over 50 countries.

E) We defined and now dominate a new aesthetic segment called non-surgical fat layer reduction, a market opportunity that will substantially grow the worldwide $20 billion category of aesthetic medicine.

F) We expanded the Company’s relationship with our key licensor Massachusetts General Hospital (MGH) to exploit incremental opportunities stemming from their cold technology IP estate.

G) We introduced a novel concept to our carefully selected channel partners (dermatologists and plastic surgeons) called S.T.E.P. (sales training & enhanced practices) – a program of practice marketing and management that is designed to leverage CoolSculpting’s appeal to “neophytes” (consumers who are first-timers to aesthetic procedures).

H) We achieved Net Revenues of $25 million in 2010.

I) We completed our initial public offering (NASDAQ:ZLTQ) in November 2011, raising slightly under $90 million (net). The premise of the IPO was to fund consumer marketing created to further unlock the “neophyte” opportunity.

J) We achieved Net Revenues of $68 million in 2011, up 172% from the prior year.

K) In February of 2012, we launched our first three test markets of our revolutionary advertising campaign: “Let’s Get Naked”.

• Prism was an early-stage venture capital partnership investing in technology and life sciences start-ups. My practice was particularly focused on medical devices. I served on the Boards of Atritech (sold to BSX), Aptus Endosystems, iScience Interventional, CoAxia, Myocor, and Insulet Corporation (NASDAQ:PODD) among others.

• Led and managed a successful leveraged buy-out of Critikon, the patient monitoring division of Johnson & Johnson (NYSE:JNJ). We acquired the business; revamped its organization, strategy, and products; and sold Critikon to GE Healthcare where it resides today. Our investors quadrupled their money in 24 months.

• Led and managed a successful leveraged buy-out of “A” Company, the orthodontic appliance (i.e., “braces”) business of Johnson & Johnson. We revived a stagnant business with the development and launch of the Damon SL System under the breakthrough “Finish First” marketing campaign. The Damon System is the leading product in the traditional orthodontic bracket market to this day. We sold “A” Company to Sybron Dental (now part of Danaher) after 24 months, with investors more than tripling their investment.

• Reported to the Non-Executive Chairman. Was recruited to lead a turnaround of Voit, a fallen sporting goods manufacturer. Led a successful business-building effort by developing a portfolio of brands (Nike, Body Glove, And Callaway Golf) across Voit’s three product segments (inflatable sports balls, swim and snorkeling products, and golf bags).
• Voit was the first sporting goods licensee of Nike’s brand, and we built the #1 inflatable ball business in the world using the famous swoosh trademark on basketballs, footballs, soccer balls, and volleyballs.
• Voit was acquired by a privately held sports brand consolidator in 1994.

• Recruited to LAG along with 5 fellow Reebok executives. Conceived, developed, and launched “LA Lights”, the first lighted children’s shoes, which became the most successful line ever in the children’s footwear business.
• Recruited to LAG along with 5 fellow Reebok executives. Conceived, developed, and launched “LA Lights”, the first lighted children’s shoes, which became the most successful line ever in the children’s footwear business.

• Bottom line responsibility for 75% of the company’s revenues children’s, women’s, and “Classics”. Developed and launched Step Reebok, which became the most popular women’s workout in the country by 1988.

• #2 executive in a global leader in alpine skis (Olin + Kneissl), ski boots (via the Hanson brand), cross country skis (via the Trak and Kneissl Cross Country brands), and tennis racquets (via the Kneissl brand). Olin was sold to K2 in 1986.

• Worked on Right Guard, the Dry Look, and Toni Home Perms.

• Taught Freshman Honors, American Literature (juniors), Introduction to Shakespeare (sophomores), Contemporary Literature (senior elective), and Poetry (seniors). Supervised a floor of a boys’ dormitory each year. Coached varsity football (Assistant Head Coach), varsity ice hockey (Head Coach), and varsity baseball (Head Coach).